Clinical Report: Preoperative HALP and LMR as Predictors of Disease-Free Survival

Overview

This study identifies preoperative HALP and LMR as independent predictors of disease-free survival (DFS) in patients with stage III colon cancer. A nomogram integrating these biomarkers with clinical variables demonstrates effective risk stratification for recurrence.

Background

Colorectal cancer is a leading cause of cancer-related mortality, particularly in stage III, where patients face significant recurrence risks despite treatment. Traditional prognostic assessments often fail to capture the heterogeneity of outcomes within this stage, necessitating the exploration of additional biomarkers that reflect host-tumor interactions.

Data Highlights

Key Findings

• HALP, SII, and LMR showed moderate discrimination for malignancy.
• Multivariable analysis identified HALP and LMR as independent predictors of DFS.
• The nomogram demonstrated good discrimination with C-index values of 0.759 and 0.743.
• Increased tumor stage and fewer chemotherapy cycles were associated with worse DFS.
• HALP integrates anemia, nutritional status, immune competence, and platelet activity.

Clinical Implications

The integration of HALP and LMR into clinical practice may enhance individualized risk assessment for recurrence in stage III colon cancer patients. This approach could inform postoperative management strategies and improve patient outcomes.

Conclusion

Preoperative HALP and LMR are valuable prognostic indicators for DFS in stage III colon cancer, supporting their use in nomogram-based risk assessment for better clinical decision-making.

References

1. Identifying Risk Factors for Lymph Node Metastasis in Early Colorectal Cancer: Development of a Predictive Nomogram and Risk Evaluation, Springer, 2024 -- https://link.springer.com/article/10.1007/s00384-024-04760-2
2. A novel nomogram utilizing log odds of positive lymph nodes to forecast overall survival in colorectal signet ring cell carcinoma patients: Insights from a SEER population-based analysis, Springer, 2024 -- https://link.springer.com/article/10.1007/s00384-024-04622-x
3. Evaluation of LNR and LODDS Predictive Models for Prognosis in Younger Patients with Locally Advanced Rectal Cancer Undergoing Neoadjuvant Treatment, Springer, 2025 -- https://link.springer.com/article/10.1007/s00384-025-04942-6
4. Updates in Surgery -- Modeling and Validation of a Column Chart for Predicting Lymph Node Metastasis in Patients with Colorectal Cancer, Springer, 2024 -- https://link.springer.com/article/10.1007/s13304-024-01884-6
5. ctDNA-based molecular residual disease and survival in resectable colorectal cancer, Nature Medicine, 2024 -- https://www.nature.com/articles/s41591-024-03254-6?utm_source=openai
6. The significant prognostic value of the hemoglobin, albumin, lymphocyte, and platelet (HALP) score in digestive system cancers: a systematic review and meta-analysis, BMC Cancer, 2025 -- https://bmccancer.biomedcentral.com/articles/10.1186/s12885-025-15068-x?utm_source=openai
7. NCCN Guidelines for Colon Cancer, 2025
8. ctDNA-based molecular residual disease and survival in resectable colorectal cancer | Nature Medicine
9. The significant prognostic value of the hemoglobin, albumin, lymphocyte, and platelet (HALP) score in digestive system cancers: a systematic review and meta-analysis | BMC Cancer | Full Text